To further explore the potential of Ki67+ Treg cells as a general predictor of ICI response and benefit in other types of cancer including NSCLC and melanoma, we calculated a Ki67+ Treg signature score using bulk RNA sequencing data and classified patients into low and high groups according to the median score. This evidence concerns the gene MKI67 and non-small cell lung carcinoma.